VIDEO: Early data on optogenetic therapy in Stargardt disease promising
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Allen C. Ho, MD, FASRS, discusses 6-month data on MCO-010 optogenetic therapy in patients with Stargardt disease.
“Patients are seeing clinically meaningful improvements in vision, improvements in visual field and Octopus visual field sensitivity, and reporting that they are seeing better patient-reported outcomes that are beneficial,” Ho said.
MCO-010 demonstrated no serious adverse events in the cohort of six patients, he said.
Collapse
Ho A. MCO-010 optogenetic therapy for severe vision loss in Stargardt disease: 6-month outcomes from the phase 2 STARLIGHT trial. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Read more about
Click Here to Manage Email Alerts